Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD
Modulating VIPergic neuroimmune signaling can ameliorate the development of hepatic steatosis induced by a surplus of fat ingestion in the diet. This neuroimmune pathway should be further investigated as a potential therapeutic avenue in MASLD.
Authors
- Dan R. Littman (ORCID: https://orcid.org/0000-0002-2850-8688)
- Varsha Raghavan (ORCID: https://orcid.org/0000-0003-4182-2038)
- Henry H. Nguyen (ORCID: https://orcid.org/0000-0002-2205-3205)
- Jhimmy Talbot (ORCID: https://orcid.org/0000-0002-0347-5074)
- Dayi Li
Institutions
- Howard Hughes Medical Institute (US)
- University of Calgary (CA)
- Fred Hutch Cancer Center (US)
- New York University (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1097/hc9.0000000000000528
- Citations
- 8
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.92
Funders
- Howard Hughes Medical Institute
- NYU Langone Medical Center
- York University
- Alberta Innovates
- National Institutes of Health